Literature DB >> 16380224

Prenatal diagnosis and management of hydronephrosis.

Jason A Pates1, Jodi S Dashe.   

Abstract

Congenital hydronephrosis is frequently amenable to prenatal diagnosis, often as early as the second trimester. Most clinicians use a renal pelvis anterior-posterior (AP) diameter of 4 mm or more prior to 20 weeks of gestation as a threshold for identifying pyelectasis. If mild dilation of the renal pelvis is an isolated finding in the second trimester, evaluation performed later in gestation is used to guide postnatal management. Since the normal renal pelvis dimensions may increase with advancing gestation, thresholds for the diagnosis are larger in the third trimester. Neonatal follow-up is typically recommended only if the fetal renal pelvis diameter exceeds a specified cut-off (e.g. 7 or 10 mm) at or beyond 34 weeks. If the measurement is less, most deem the pyelectasis physiologic or normal. However, it has been suggested that fetuses with early renal pelvis dilation that resolved during pregnancy might also benefit from postnatal surveillance. The newborn evaluation for hydronephrosis may be time consuming, invasive, and costly; however, it can often prevent sequelae from congenital uropathy.

Entities:  

Mesh:

Year:  2005        PMID: 16380224     DOI: 10.1016/j.earlhumdev.2005.11.003

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  11 in total

1.  Should prenatal hydronephrosis that resolves before birth be followed postnatally? Analysis and comparison to persistent prenatal hydronephrosis.

Authors:  Patrick L Scarborough; Elizabeth Ferrara; Douglas W Storm
Journal:  Pediatr Nephrol       Date:  2015-04-01       Impact factor: 3.714

Review 2.  Is it Always Necessary to Treat an Asymptomatic Hydronephrosis Due to Ureteropelvic Junction Obstruction?

Authors:  Yogesh Kumar Sarin
Journal:  Indian J Pediatr       Date:  2017-05-03       Impact factor: 1.967

3.  Urinary neutrophil glatinase-associated lipocalin level (uNGAL) may predict the severity of congenital hydronephrosis in infants.

Authors:  Rahimpour Amiri; Hiwa Hosseini; Zahra Sanaei; Saba Shamahmoudi; Ghasem Solgi
Journal:  Am J Clin Exp Immunol       Date:  2021-02-15

4.  A New Grading System for the Management of Antenatal Hydronephrosis.

Authors:  Joana Dos Santos; Rulan S Parekh; Tino D Piscione; Tarek Hassouna; Victor Figueroa; Paula Gonima; Isis Vargas; Walid Farhat; Norman D Rosenblum
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-31       Impact factor: 8.237

5.  Clinical importance of pyelocalyceal dilation diagnosed by postnatal ultrasonographic screening of the urinary tract.

Authors:  Kristina Drnasin; Mirna Saraga-Babić; Marijan Saraga
Journal:  Med Sci Monit       Date:  2013-02-19

6.  Efficacy of prenatal ultrasonography in diagnosing urogenital developmental anomalies in newborns.

Authors:  Artur Beke; Fanni Rebeka Eros; Barbara Pete; Istvan Szabo; Eva Gorbe; Janos Rigo
Journal:  BMC Pregnancy Childbirth       Date:  2014-02-24       Impact factor: 3.007

7.  Prognostic value of three-dimensional ultrasound for fetal hydronephrosis.

Authors:  Junmei Wang; Weiwen Ying; Daxing Tang; Liming Yang; Dongsheng Liu; Yuanhui Liu; Jiaoe Pan; Xing Xie
Journal:  Exp Ther Med       Date:  2015-01-05       Impact factor: 2.447

8.  Diagnosis of 65 cases of ampullary renal pelvis after postnatal follow-up of 1,167 newborn infants with prenatally suspected hydronephrosis.

Authors:  Lei Zhang; Chao Liu; Fujiang Li; Xiang Li; Chao Sun; Hao Sun
Journal:  Exp Ther Med       Date:  2014-11-18       Impact factor: 2.447

9.  Postnatal Evaluation and Outcome of Prenatal Hydronephrosis.

Authors:  Simin Sadeghi-Bojd; Abdol-Mohammad Kajbafzadeh; Alireza Ansari-Moghadam; Somaye Rashidi
Journal:  Iran J Pediatr       Date:  2016-03-05       Impact factor: 0.364

10.  Prenatal diagnosis of a rare form of congenital mid-ureteral stricture: a case report and literature revisited.

Authors:  Milena Brugnara; Mariangela Cecchetto; Riccardo Manfredi; Michele Zuffante; Vassilios Fanos; Angelo Pietrobelli; Marco Zaffanello
Journal:  BMC Urol       Date:  2007-06-08       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.